Remimazolam besylate - PAION

Drug Profile

Remimazolam besylate - PAION

Alternative Names: CNS 7056X; CNS-7056; CNS-7056B; ONO-2745

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Hana Pharm; PAION; R-Pharm; Yichang Humanwell Pharmaceutical
  • Class Benzodiazepines; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaesthesia; Sedation

Most Recent Events

  • 06 Nov 2018 Remimazolam besylate - PAION is available for licensing in Canada, China, Commonwealth of Independent States, Japan, Middle East, North Africa, Russia, South Korea, Turkey, USA as of 06 Nov 2018. www.paion.com
  • 06 Nov 2018 R-Pharm announces intention to submit MAA to Russian Ministry of Healthcare for Anaesthesia in the first quarter of 2019
  • 09 Oct 2018 Phase-III clinical trials in Anaesthesia in Netherlands (IV) (EudraCT2018-000174-29) (NCT03661489)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top